MedTrace Logo

Health Benefits of Repeated Treatment in Pediatric Schistosomiasis

NCT01424410 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 360

Last updated 2017-06-14

No results posted yet for this study

Summary

Objective and Hypotheses: This project has the overall objective of implementing and evaluating new approaches to reducing the current and future burden of urinary schistosomiasis in young children using the antihelminthic drug praziquantel. The investigators hypotheses are that (1) praziquantel treatment will be as effective in children 1 to 5 years of age (who are routinely excluded from schistosomiasis control programmes) as it is in older 6-10 year old children and (2) two treatments will be more effective than a single treatment, especially in children 1 to 5 years of age.

Conditions

  • Schistosomiasis

Sponsors & Collaborators

  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV

  • University of Zimbabwe

    collaborator OTHER

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • Francisca Mutapi, PhD · University of Edinburgh

Eligibility

Min Age
1 Year
Max Age
10 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2014-07-31
Completion
2014-11-30

Countries

  • Zimbabwe

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01424410 on ClinicalTrials.gov